Nuvation Bio Inc. NUVB
5.74
0.01
0.17%
as of 25 Sep
- Market cap
- $2.0B
- P/E
- 0.0×
Follow NUVB
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(52.49%) | (53.18%) | (39.51%) | (47.81%) | |
| (37.08%) | (36.04%) | (26.48%) | (21.53%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(42.65%) | (41.77%) | (28.48%) | (23.40%) | |
Average Days of Receivables |
189.00 | 112.35 | 66.30 | 68.13 | |
Free Cash Flow per Share |
(0.56) | (0.51) | (0.36) | (0.35) | |
Free Cash Flow |
(190.25) | (173.78) | (126.06) | (120.92) | |
Capital Expenditures |
(0.25) | (0.35) | (0.33) | (0.40) | |
Piotroski F-Score |
4.00 | 4.00 | 4.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(20.48%) | (19.53%) | (13.87%) | (10.36%) | |
Accounts Receivable Turnover |
2.96 | 3.53 | 9.10 | 8.85 | |
Accounts Payable Turnover |
0.88 | 1.18 | 0.80 | 1.16 | |
Inventory Turnover |
0.00 | 0.00 | 1.66 | 1.96 | |
Average Days of Payables |
458.23 | 372.11 | 620.60 | 219.64 | |
Days of Inventory on Hand |
170.34 | 447.95 | 438.28 | 361.57 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
411.65% | 182.99% | 87.77% | 75.84% | |
Selling, General and Administrative Expense of Revenue |
513.59% | 240.95% | 107.99% | 93.34% | |
Share Based Compensation of Revenue |
142.42% | 57.06% | 25.92% | 20.90% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.87 | 0.85 | 0.86 | 0.80 | |
Depreciation/Fixed assets |
3.13 | 4.26 | 5.51 | 4.84 | |
Capex/Depreciation |
(0.14) | (0.15) | (0.11) | (0.12) | |
Revenue per Share |
0.08 | 0.18 | 0.41 | 0.49 | |
Operating CF per Share |
(0.55) | (0.51) | (0.36) | (0.35) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.00 | |
Net Profit Margin |
(813.07%) | (325.31%) | (102.06%) | (88.19%) |
Columns are period end dates